Inhibitor – Page 4

Arcus Biosciences Advances Promising Kidney Cancer Drug Casdatifan After Gilead Opts Out

8 months ago talkbio0Tagged Arcus, casdatifan, cell renal cell carcinoma, Clinical Trials, Conventional (Clear Cell) Renal Cell Carcinoma, HIF-2a, Inhibitor, Malignant neoplasm of kidney

Arcus Biosciences, casdatifan, HIF-2a inhibitor, kidney cancer, clear cell renal cell carcinoma (ccRCC), Gilead Sciences, clinical trial data, $150 million stock offering

FDA Approves Ono’s Romvimza for Rare Joint Tumor, Challenging Daiichi Sankyo’s Turalio

8 months ago talkbio0Tagged Approved, CSF1, CSF1 gene, Daiichi, Dosage Forms, Fibrous histiocytoma of tendon sheath, Giant Cell Tumors, Inhibitor, Joint Tumor, Romvimza, Sankyo, tenosynovial, Turalio, United States Food and Drug Administration, Vimseltinib

Romvimza, vimseltinib, tenosynovial giant cell tumor (TGCT), Ono Pharmaceutical, FDA approval, Daiichi Sankyo, Turalio, CSF1 inhibitor, rare joint tumor

Bristol Myers Squibb’s Opdualag Fails Phase 3 Trial in Adjuvant Melanoma Treatment

8 months ago talkbio0Tagged Clinical Trials, Failure (biologic function), Immunologic Adjuvants, Immunotherapy, Inhibitor, lymphocyte-activation gene 3 protein, human, melanoma, Myers, Opdualag, squibb

Opdualag, Bristol Myers Squibb, melanoma, clinical trial failure, LAG-3 inhibitor, immunotherapy, adjuvant treatment

Pfizer’s Talzenna-Xtandi Combo Shows Significant Survival Benefit in Advanced Prostate Cancer

8 months ago talkbio0Tagged Clinical Trials, Gene Mutation, Inhibitor, Metastatic castration-resistant prostate cancer, Overall Survival, PARP1 gene, recombinational repair, TALAPRO-2, Talzenna, Xtandi

Talzenna, Xtandi, metastatic castration-resistant prostate cancer (mCRPC), overall survival, TALAPRO-2 trial, PARP inhibitor, homologous recombination repair (HRR) gene mutations

SpringWorks Therapeutics Secures FDA Approval for Gomekli to Treat NF1-Related Tumors

8 months ago talkbio0Tagged Approved, disease treatment, Gomekli, Infrequent, Inhibitor, MEK, mirdametinib, Neurofibromatosis 1, Plexiform, Plexiform Neurofibroma, SpringWorks, United States Food and Drug Administration

SpringWorks Therapeutics, Gomekli, mirdametinib, FDA approval, neurofibromatosis type 1 (NF1), plexiform neurofibromas (PN), rare disease treatment, MEK inhibitor

FDA Approves SpringWorks’ Gomekli for Adult and Pediatric NF1-PN Patients

8 months ago talkbio0Tagged Approved, Gomekli, Inhibitor, MEK, mirdametinib, neurofibroma, Plexiform, SpringWorks, United States Food and Drug Administration

Gomekli, mirdametinib, neurofibromatosis type 1, plexiform neurofibromas, FDA approval, SpringWorks Therapeutics, MEK inhibitor

Boehringer Ingelheim’s Nerandomilast Succeeds in Second Phase III Lung Fibrosis Trial, Paving Way for FDA Approval

8 months ago talkbio0Tagged Approved, Boehringer, FIBRONEER-ILD, fibrosing, Improvement, Ingelheim, Inhibitor, nerandomilast, PF-ILDs, Phase 3 Clinical Trials, phosphodiesterase 4B, Progressive, Respiratory physiology, United States Food and Drug Administration

Nerandomilast, Boehringer Ingelheim, Phase III trial, FIBRONEER-ILD, progressive fibrosing interstitial lung diseases (PF-ILDs), lung function improvement, FDA approval, phosphodiesterase 4B (PDE4B) inhibitor